Yu-Tso Liao1,2, Yu-Lin Lin3, John Huang4, Ji-Shiang Hung4, Been-Ren Lin5. 1. Division of Colorectal Surgery, Department of Surgery, Biomedical Park Hospital, National Taiwan University Hospital, Hsinchu, Taiwan, Republic of China. 2. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taiwan, Taipei, Republic of China. 3. Division of Hematology and Oncology, Department of Internal Medicine, Cardinal Tien Hospital, New Taipei, Taiwan, Republic of China. 4. Division of Colorectal Surgery, Department of Surgery, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China. 5. Division of Colorectal Surgery, Department of Surgery, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China. beenrenlin@ntu.edu.tw.
Abstract
PURPOSE: Current guidelines suggest that adjuvant chemotherapy (AC) be administered to all locally advanced (clinically T3-4 or N-positivity) rectal cancer patients undergoing neoadjuvant chemoradiotherapy (nCRT) and radical surgical resection regardless of the final pathological staging (yp staging). This study aimed to evaluate the necessity of AC for ypT0-2N0 rectal cancer. METHODS: Patients with ypT0-2N0 rectal cancer, who received nCRT and radical surgical resection, were recruited retrospectively at a university hospital. The main outcome was to evaluate the 5-year overall survival (OS) and disease-free survival (DFS) between ypT0-2N0 rectal cancer patients with AC and those without AC. We also identified potential independent prognostic factors associated with poor outcomes. RESULTS: One hundred and ten ypT0-2N0 rectal cancer patients (ypT0: n = 6; ypT1: n = 44; ypT2: n = 60) were followed up for a median of 60 months. No significant difference was observed in DFS and 5-year OS between patients with AC and those without AC. The risk of recurrence was associated with the postoperative pathological staging (0% with ypT0, 2.4% with ypT1, and 10% with ypT2). In the multivariate analysis, retrieval of < 12 lymph nodes was an independent favorable prognostic factor, which correlated with a higher OS (HR: 2.263; 95% CI: 1.093-4.687, P = 0.028). Intra-tumor lymphovascular and perineural invasion were poor prognostic markers for shorter DFS (HR: 5.940; 95% CI: 1.150-30.696, P = 0.033). CONCLUSION: Postoperative AC is not required for patients with ypT0-2N0 rectal cancer downstaged by nCRT, especially in those without poor prognostic factors.
PURPOSE: Current guidelines suggest that adjuvant chemotherapy (AC) be administered to all locally advanced (clinically T3-4 or N-positivity) rectal cancerpatients undergoing neoadjuvant chemoradiotherapy (nCRT) and radical surgical resection regardless of the final pathological staging (yp staging). This study aimed to evaluate the necessity of AC for ypT0-2N0 rectal cancer. METHODS:Patients with ypT0-2N0 rectal cancer, who received nCRT and radical surgical resection, were recruited retrospectively at a university hospital. The main outcome was to evaluate the 5-year overall survival (OS) and disease-free survival (DFS) between ypT0-2N0 rectal cancerpatients with AC and those without AC. We also identified potential independent prognostic factors associated with poor outcomes. RESULTS: One hundred and ten ypT0-2N0 rectal cancerpatients (ypT0: n = 6; ypT1: n = 44; ypT2: n = 60) were followed up for a median of 60 months. No significant difference was observed in DFS and 5-year OS between patients with AC and those without AC. The risk of recurrence was associated with the postoperative pathological staging (0% with ypT0, 2.4% with ypT1, and 10% with ypT2). In the multivariate analysis, retrieval of < 12 lymph nodes was an independent favorable prognostic factor, which correlated with a higher OS (HR: 2.263; 95% CI: 1.093-4.687, P = 0.028). Intra-tumor lymphovascular and perineural invasion were poor prognostic markers for shorter DFS (HR: 5.940; 95% CI: 1.150-30.696, P = 0.033). CONCLUSION: Postoperative AC is not required for patients with ypT0-2N0 rectal cancer downstaged by nCRT, especially in those without poor prognostic factors.
Authors: Willem van Gijn; Corrie A M Marijnen; Iris D Nagtegaal; Elma Meershoek-Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm J T Rutten; Lars Påhlman; Bengt Glimelius; Cornelis J H van de Velde Journal: Lancet Oncol Date: 2011-05-17 Impact factor: 41.316
Authors: Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets Journal: Lancet Oncol Date: 2010-08-06 Impact factor: 41.316
Authors: B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner Journal: J Natl Cancer Inst Date: 1988-03-02 Impact factor: 13.506
Authors: Viviane Hess; Ralph Winterhalder; Roger von Moos; Lucas Widmer; Priska Stocker; Monika Jermann; Richard Herrmann; Dieter Koeberle Journal: Clin Colorectal Cancer Date: 2016-07-30 Impact factor: 4.481